Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Roth Capital reissued a “buy” rating on shares of Bio-Path in a research note on Friday, March 17th.

Bio-Path Price Performance

Shares of NASDAQ:BPTH opened at $1.71 on Wednesday. The company’s 50 day simple moving average is $1.48 and its 200 day simple moving average is $1.62. The stock has a market capitalization of $13.61 million, a price-to-earnings ratio of -0.81 and a beta of 1.30. Bio-Path has a 1 year low of $1.18 and a 1 year high of $4.48.

Bio-Path (NASDAQ:BPTH – Get Rating) last announced its quarterly earnings data on Friday, March 31st. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.08). As a group, analysts anticipate that Bio-Path will post -1.91 EPS for the current fiscal year.

Institutional Trading of Bio-Path

A number of hedge funds and other institutional investors have recently modified their holdings of BPTH. Virtu Financial LLC bought a new stake in shares of Bio-Path during the first quarter worth $38,000. Renaissance Technologies LLC bought a new stake in shares of Bio-Path during the second quarter worth $70,000. Mount Yale Investment Advisors LLC bought a new stake in shares of Bio-Path during the third quarter worth $81,000. Finally, Citadel Advisors LLC bought a new stake in shares of Bio-Path during the third quarter worth $35,000. Institutional investors own 6.42% of the company’s stock.

About Bio-Path

(Get Rating)

Bio-Path Holdings, Inc is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.